Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol 2024
13.06.2024
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
13.06.2024
J Neurol 2024
Gantenbein Andreas R, Bonvin Christophe, Kamm Christian Philipp, Schankin Christoph J, Zecca Chiara, Zieglgänsberger Dominik, Merki-Feld Gabriele Susanne, Pohl Heiko, Rudolph Nicole, Ryvlin Philippe, Agosti Reto, Schäfer Elisabeth, Meyer Ina, Kulartz-Schank Monika, Arzt Michael E
Weiter
